¥µ¥¤¥ÈÆâ´ØÏ¢¥Ú¡¼¥¸ °äÅÁÀ­¼À´µ¤â¤¯¤¸ OMIA¡¡1¡Á100 OMIA¡¡101¡Á200 OMIA¡¡201¡Á300 OMIA¡¡301¡Á400 OMIA¡¡401¡Á500
OMIA¡¡501¡Á600 OMIA¡¡601¡Á700 OMIA¡¡701¡Á SiriuDog 001¡Á070 SiriuDog 071¡Á140 SiriuDog 141¡Á210 SiriuDog 211¡Á280
SiriuDog 281¡Á334 ¡üʬÎàÊÌ-ÆâʬÈç ¸¡ººµ¡´Ø°ìÍ÷ ¹ñÆâ°äÅÁ»Ò¸¡ººÉµ¤°ìÍ÷ ¹ñÆâ°äÅÁ»Ò¸¡ºº¸¤¼ïÊÌ °äÅÁÉÂÍѸì²òÀâ
¸¤¼ïÊÌ°äÅÁÀ­¼À´µ(07ǯÅÙÅÐϿƬ¿ô½ç) 1°Ì¥À¥Ã¥¯¥¹¥Õ¥ó¥È 2°Ì¥Á¥ï¥ï 3°Ì¥×¡¼¥É¥ë 4°Ì¥è¡¼¥¯¥·¥ã¡¼¥Æ¥ê¥¢ 5°Ì¥Ý¥á¥é¥Ë¥¢¥ó


Dog Genetic disorder

2017ǯ9·î¸½ºß¤Ç707¼ï³Îǧ¤µ¤ì¤Æ¤¤¤ë¸¤¤Î°äÅÁ·Á¼Á¡¢°äÅÁÀ­¼À´µ
¤Î¤¦¤Á¡¢¼ç¤ËÆâʬÈ硦Âå¼Õ¡¦¥Û¥ë¥â¥óÀ­¤Îɵ¤¤Ë´Ø¤¹¤ë¤â¤Î

ºîÀ®¡¡¡¡¡¡¡¡2006ǯ12·î
ºÇ½ª¹¹¿·¡¡¡¡2017ǯ9·î

¡¦OMIAOnline Mendelian Inheritance in Animals¡¡¸¤¤Î°äÅÁ·Á¼Á
http://omia.angis.org.au/
¥ê¥¹¥È¤ÎÉÂ̾¡¦ÂåɽŪ¤Ê¾É¾õ¡¦°äÅÁ·Á¼°¡¦¤è¤¯¸¦µæ¤µ¤ì¤Æ¤¤¤ë¸¤¼ï¤äưʪ¼ï¤ÎÏÂÌõ¤È¥á¥â

¡ü¤³¤Î¥Ú¡¼¥¸¤Î¾ðÊó¤ò»ÈÍѤ¹¤ëºÝ¤Ï°ìÉôʬ¤Ç¤¢¤Ã¤Æ¤âɬ¤º¤³¤³¤ÎURL¤òÌÀµ­¤·¤Æ¤¯¤À¤µ¤¤¡£¾ðÊó¤ÎÆȤêÊ⤭¤Ë¤è¤ë¥È¥é¥Ö¥ëËɻߤΤ¿¤á¤Ç¤¹¡£
¡ü¸¡º÷¤«¤éľÀܤ³¤Î¥Ú¡¼¥¸¤ËÍ褿¾ì¹ç¤Ï¤ª¼ê¿ô¤Ç¤¹¤¬°äÅÁÀ­¼À´µ¤â¤¯¤¸¤ò°ìÅÙ¤´³Îǧ´ê¤¤¤Þ¤¹¡£
.
38
60 114 83 6 35 22 30 58 85 79 23 35 15 24
·Á¼Á ·ì´É¡¦·ì±Õ Ǿ¿À·Ð ¶Ú¹ü³Ê¡¦·ë¹çÁÈ¿¥ ¸ÆµÛ´ï ½Û´Ä´ï ¾Ã²½´ï ¿ÕǢϩ ÀèÅ·´ñ·Á ÆâʬÈ硦Âå¼Õ ´ã¡¦¼ª¡¦É¡ ¼ðáç ÈéÉæ ¥¢¥ì¥ë¥®¡¼¡¦Ì鱅 ¤½¤Î¾


ÆâʬÈ硦Âå¼Õ¡¡¡¡¡¡¡¡¡¡85
ÄÌÈÖ ¼À ´µ ̾ ¼ç ¤Ê ¾É ¾õ È÷¡¡¡¡¡¡¡¡¡¡¹Í °äÅÁ·ÁÂÖ ¼ç¤Ê³ºÅö¸¤¼ï
10 Acromegaly
¥¢¥¯¥í¥á¥¬¥ê¡¼
ËöüÈîÂç¾É
´éÌ̤Υѡ¼¥Ä¤ä­Àè¤Ê¤É¤¬½ù¡¹¤ËÈîÂç¡¢²¼¿âÂÎ¥Û¥ë¥â¥ó°Û¾ïʬÈ礬¼ç°ø¡£ À®Ä¹¥Û¥ë¥â¥ó¤Î²á¾ê»ºÀ¸¤Ëµ¯°ø¤¹¤ëÆÃÄê¤ÎÂΤÎÁÈ¿¥¤Î²á¾ê¤ÊÀ®Ä¹¡£¹â»é·ì¾É¤ä´Î¾ã³²¡¦ÅüǢɡ¦Ç¢Êø¾É¤Î¿´ÇÛ¡£È¯¾ðµÙ»ß´ü¤Î´Ö¤Î»èüµðÂç¾É¡¢Â¿°û¿Ǣ¡£(*¥¢¥ë¥®¥Ë¥ó¡¦¥Ð¥½¥×¥ì¥·¥ó(AVP)¥ì¥Ù¥ë¤ÎÉÔ½½Ê¬¤Ê¾å¾º*) ¾ïÀ÷¿§ÂÎÀ­¡¢unknown ¥Ó¡¼¥°¥ë¡¢G¥·¥§¥Ñ¡¢Ç­
11 ACTH-independent adrenal Cushing syndrome, somatic
ACTH Èó°Í¸Éû¿Õ¥¯¥Ã¥·¥ó¥°¾É¸õ·²
¿©ÍßÁý¡Ê¿¿©¡Ë¡¢Â¿°û¡¦Â¿Ç¢¡¢Á´¿ÈÀ­¤Îº¸±¦ÂоÎæÌÓ¡¢Çö¤¯¥·¥ï¤¬´ó¤ëÈéÉ桢ʢÉô¤¬ËĤì¤ë¥Ó¥äîÂη¿ Éû¿Õ¤¬¸¶°ø¤Ç¥³¥ë¥Á¥¾¡¼¥ë¤ò²á¾ê¤ËʬÈ礹¤ë¾õÂÖ¡£¤Á¤Ê¤ß¤Ë¾¤Ï¡¢²¼¿âÂΤ«¤éÉû¿ÕÈé¼Á»É·ã¥Û¥ë¥â¥óACTH¤¬²á¾ê¤ËʬÈ礵¤ì¤½¤Î·ë²Ì¥³¥ë¥Á¥¾¡¼¥ë¤¬Áý¤¨¤ë¾õÂÖ¤òACTH°Í¸À­¥¯¥Ã¥·¥ó¥°¾É¸õ·²¡¢²¼¿âÂΰʳ°¤«¤éACTH¤¬²á¾ê¤ËʬÈ礵¤ì¤ëɵ¤¤ò°Û½êÀ­ACTH¾É¸õ·²¡¢ unknown ¿
12 Adrenal cortical atrophy
Éû¿ÕÈé¼Á°à½Ì¾É
ºÇ½ªÅª¤Ë¤Ï°×´¶À÷À­ Éû¿ÕÈé¼Á¥Û¥ë¥â¥ó¤¬ºî¤é¤ì¤Ê¤¤¤Ê¤É¤Ê¤ó¤é¤«¤ÎÍýͳ¤Ë¤è¤êÉû¿ÕÈé¼Á¤Î»Å»ö¤¬¤Ê¤¯¤Ê¤ë¤³¤È¤Ç°à½Ì¤·¤Æ¤¤¤¯¡£Éû¿Õ¤Ï¾®¤µ¤Ê´ï´±¤Ê¤Î¤Ç°à½Ì¤·¤Æ¤¤¤ë¤«¤É¤¦¤«¤òÃΤë¤Î¤Ï¥Ò¥È¤Ç¤âÆñ¤·¤¤ unknown ¿
17 Alloxan-diabetes
¥¢¥í¥­¥µ¥óÅüÇ¢
* ¥¤¥ó¥¹¥ê¥ó°Í¸·¿ÅüǢɤǵõ·ìÀ­´§Æ°Ì®¼À´µ¤Î¸¶°ø¤È¤Ê¤ë * *
21 Alpha-1-antitrypsin deficiency
¥¢¥ë¥Õ¥¡1¥¢¥ó¥Á¥È¥ê¥×¥·¥ó·ç»¾É
´Î¾ã³²¡¢¸ÆµÛº¤Æñ¡¢ÓÒÅÇ¡¦²¼Î¡¡¦Ê¢¿å¡¦²«áÕ¡¦½Ð·ì·¹¸þ ´Î¹ÅÊѤäÌçÌ®°µÐ¶¿Ê¾É¤Ç¿¤¯¤ÏÀ®Ä¹´ü¤Ç»àË´¡£¥¿¥ó¥Ñ¥¯¼Á¤òʬ²ò¤¹¤ë¹ÚÁÇ¡Ê¥×¥í¥Æ¥¢¡¼¥¼¡Ë¤ÎºîÍѤòÍÞÀ©¤¹¤ë¥¢¥ë¥Õ¥¡1¡¾¥¢¥ó¥Á¥È¥ê¥×¥·¥ó¤Î·ç»¡£ÆäËÇÙ¤ä´Î¡¤ÎÁÈ¿¥¤Ë¾ã³²¤¬À¸¤¸¡¢´Î¡¤¬¤³¤Î¹ÚÁǤòºÙ˦¤Î³°¤ËʬÈç¤Ç¤­¤Ê¤¯¤Ê¤ê¹ÚÁǤ¬´ÎºÙ˦Æâ¤Ë¤¿¤Þ¤ê¡¢´ÎºÙ˦¤Î»½ý¤ò°ú¤­µ¯¤³¤¹¡£ ¾ïÀ÷¿§ÂÎÀ­¡¢unknown A¥³¥Ã¥«¡¼
24 Amyloidosis
¥¢¥ß¥í¥¤¥É¾É¡¢¥¢¥ß¥í¥¤¥É¡¼¥·¥¹
¡´ï¤Ë¤è¤Ã¤Æ¾É¾õ¤ÏÍÍ¡¹¤À¤¬¿Õ¡¤Î¾ì¹ç¤Ï¥Í¥Õ¥í¡¼¥¼¤ä¿ÕÉÔÁ´¡¢¿´Â¡¤Î¾ì¹ç¤ÏÉÔÀ°Ì®¤ä¿´ÉÔÁ´¡¢¿À·Ð¾É¾õ¤È¤·¤Æ¤Ï¼º¿À¡¢ÌëÇ¢¡¢´¶³Ð¤¬Æߤ¯¤Ê¤ë¡¢°ßIJ¾ã³²¡¢Ëö¾¿¿À·Ð¤ä¼«Î§¿À·Ð¤Î¾ã³²(¼ê­¤Î¤·¤Ó¤ì¡¢Ëãáã¡¢ÇÓÇ¢¤Î°Û¾ï¡¢ÊØÈë¡¢²¼Î¡)¡¢±¿Æ°¾ã³² Âå¼ÕÀ­´Î¼À´µ¡£¥¢¥ß¥í¥¤¥É¤È¤¤¤¦°Û¾ï¥¿¥ó¥Ñ¥¯¤¬Â¡´ï¤ËÄÀÃ夷¡¢¤½¤Î¡´ï¤¬Àµ¾ï¤Ëµ¡Ç½¤·¤Ê¤¯¤Ê¤ëɵ¤¤ÎÁí¾Î¡£Á´¿ÈÀ­¤È¸Â¶ÉÀ­(¸Â¶ÉÀ­¤Ë¥¢¥ë¥Ä¥Ï¥¤¥Þ¡¼É¤ä¥×¥ê¥ª¥ó¤Ê¤É)¡£Ìȱ֥°¥í¥°¥ê¥óÃÁÇò¤È¤Ï°Û¤Ê¤ëÆüì¤ÊNËöü¥¢¥ß¥Î»ÀÇÛÎó¤ò¤â¤Ä¥¢¥ß¥í¥¤¥É¡£¼çÍפʥ¢¥ß¥í¥¤¥É¾É¤Ë¤Ï3¥¿¥¤¥×¤¢¤ë¡£Ëö¾¿À­´¶³Ð¤ª¤è¤Ó±¿Æ°¿À·Ð¾ã³²¡¢¼«Î§¿À·Ð¾ã³²¡¢¿´·ì´É·Ï¤ª¤è¤Ó¿Õ¥¢¥ß¥í¥¤¥É¡£¼êº¬´É¾É¸õ·²¤È¾Ë»ÒÂΰ۾ï¤âµ¯¤³¤ê¤¦¤ë ¾ïÀ÷¿§ÂÎÀ­¡¢unknown ½©Åĸ¤¡¢¥Ó¡¼¥°¥ë¡¢C¥·¥ã¡¼¥Ú¥¤¡¢Ç­¡¢·Ü
25 Amyloidosis, AA
Æó¼¡À­¥¢¥ß¥í¥¤¥É¾É¡¢¥¢¥ß¥í¥¤¥É¡¼¥·¥¹
Ʊ¾å ËýÀ­·Ð²á¤ò¤È¤ë²½Ç¿À­¼À´µ¡¢ËýÀ­´¶À÷¾É¡¢ÁÈ¿¥Ç˲õÀ­¼À´µ¤Ë¸¶°ø¡£¥¢¥ß¥í¥¤¥É¤¬¤Ä¤¯¤é¤ì¤ë¸¶°ø¤Ï¤Ï¤Ã¤­¤ê¤·¤Æ¤¤¤Ê¤¤¤¬¤Ê¤ó¤é¤«¤ÎÌȱÖÈ¿±þ¤È´Ø¤ï¤ê¤¬¤¢¤ë¤È¤µ¤ì¤Æ¤¤¤ë¡£Æ°Êª¤Ç¤Ï¸¶È¯À­¥¢¥ß¥í¥¤¥É¡¼¥·¥¹¤Ïµ©¤Ç¤Û¤È¤ó¤É¤¬Æó¼¡À­¡£(Æó¼¡À­¡á³ȯÀ­¡£ÂеÁ¸ì¤Ï¸¶È¯À­(ºÇ½é¤Î¡¢Âè°ì¤Î)) ¾ïÀ÷¿§ÂÎÀ­¡¢unknown C¥·¥ã¡¼¥Ú¥¤
26 Amyloidosis, renal
¿ÕÀ­¥¢¥ß¥í¥¤¥É¾É¡¢¥¢¥ß¥í¥¤¥É¡¼¥·¥¹
̵µ¤ÎÏ¡¢ÂνŸº¾¯¡¢Â¿°û¿Ǣ¡¢»åµåÂΤäÇ¢ºÙ´ÉÉÕ¶á¤Ë¥¢¥ß¥í¥¤¥É¤¬ÄÀÃ夹¤ë¤³¤È¤Ë¤è¤ë¥Í¥Õ¥í¡¼¥¼¡¢¿ÕÉÔÁ´ Ä̾ï5ºÐ°Ê¾å¤Çȯ¾É¡¢»õ·Ô¤¬´¥Á礷¤¿¾ì¹çÄãÂβ¹¡¦ÓÒÅÇ¡¦²¼Î¡¡¦¸ý¤ÎÄÙáç¤â¸«¤é¤ì¤ë unknown ¾ïÀ÷¿§ÂÎÀ­¡¢ C¥·¥ã¡¼¥Ú¥¤¡¢Ç­¡¢µí
61 Bardet-Biedl syndrome 4
¥Ð¥ë¥Ç¡¼¡¦¥Ó¡¼¥É¥ë¾É¸õ·²
Gene: BBS4
ÈîËþ¡¢ÌÖË쿧ÁÇÊÑÀ­¾É¡¢ËýÀ­¿Õ¾ã³²¡¢À­Á£µ¡Ç½Äã²¼¾É¡Ê̵ȯ¾ð¡Ë¡¢Â¿»Ø¾É¡¦¹ç»Ø¾É
¥Ò¥È¤Ç¤ÏÃÎǽ¾ã³²¤òȼ¤¦AR¤¬ÃΤé¤ì¤Æ¤¤¤ë¡ÊÆñÉÂÂоݡˢªAR³ÎÄê07/17 AR ¥×¡¼¥ê¡¼
158 Cushing disease
¥¯¥Ã¥·¥ó¥°ÉÂ
½é´ü¤Ï¿©Íߤä°û¿åÎ̤äÇ¢Î̤ÎÁý²Ã¡¢Ê¢ÉôËÄËþ¡¢º¸±¦ÂоݤÇáڤߤΤʤ¤Ã¦ÌÓ¡¢³°½ýÀפÎÈé²¼½Ð·ì¡¢¤Ë¤­¤ÓÍͤΤǤ­¤â¤Î¡¢ÈéÉæ¤Î¹õ¤º¤ß¤Ê¤É #¥¯¥Ã¥·¥ó¥°¾É¸õ·² ²¼¿âÂμðáç¤Ë¤è¤ëÉû¿ÕÈé¼Á»É·ã¥Û¥ë¥â¥óACTH¤ÎʬÈç²á¾ê¤¬Æó¼¡Åª¤ËÉû¿ÕÈé¼Á¤òÈîÂ礵¤»Åü¼Á¥³¥ë¥Á¥³¥¤¥É¤¬²á¾êʬÈ礵¤ì¤ë¡£²¼¿âÂΤ¬¸¶È¯¤Ê¤Î¤ÇÉû¿ÕÈé¼Á¤Ë°ì»þŪ¤ÊÉÂÊѤÏ̵¤¤¡£¥¯¥Ã¥·¥ó¥°¾É¸õ·²¤È¤Î¾É¾õ¤Îº¹¤Ï¤Ê¤¤ unknown ¿
167 Deficiency of cytosolic arylamine N-acetylation
¥¢¥ê¡¼¥ë¥¢¥ß¥ó¤ÈN -¥¢¥»¥Á¥ë¥È¥é¥ó¥¹¥Õ¥§¥é¡¼¥¼¤Î·ç˳
¢¨Éµ¤¤Ç¤Ï¤Ê¤¤ Genes: NAT1, NAT2
¤¹¤Ù¤Æ¤Î¸¤¤Ï¾åµ­°äÅÁ»Ò¤ò»ý¤¿¤º¡¢¤½¤·¤Æ¤½¤Î°äÅÁ»Ò¤Ï¾ïÀ÷¿§ÂÎÎôÀ­°äÅÁ¤¹¤ë¤È¤¤¤¦¸¦µæ
AR Á´
177 Diabetes
ÅüÇ¢ÉÂ
¿°û¿Ǣ¡¢¿©ÍßÁý²½(½é´ü)¤¹¤ë¤¬Á餻¤Æ¤¯¤ë¡¢¸µµ¤¾ÃÄÀ¡¢·ìÅüÃͤξ徺 ÅüÂå¼Õ¤Î°Û¾ï¤Ë¤è¤Ã¤Æµ¯¤³¤ë¤È¤µ¤ì¡¢·ìÅüÃÍ(·ì±ÕÃæ¤Î¥Ö¥É¥¦ÅüÇ»ÅÙ)¤¬ÉÂŪ¤Ë¹â¤Þ¤ë¤³¤È¤Ë¤è¤Ã¤ÆÍÍ¡¹¤ÊÆÃħŪ¤Ê¹çÊ»¾É¤ò¤­¤¿¤¹ unknown *
179 Diabetes mellitus
¿¿À­ÅüÇ¢ÉÂ
¿°û¿Ǣ¡¢¿©ÍßÁý²½(½é´ü)¤¹¤ë¤¬Á餻¤Æ¤¯¤ë¡¢¸µµ¤¾ÃÄÀ¡¢·ìÅüÃͤξ徺 ¥¤¥ó¥¹¥ê¥óʬÈ礢¤ë¤¤¤ÏºîÍѤÎÉÔ­¤Ë¤è¤ë»ý³Ū¹â·ìÅü¡£¥±¥È¥óÃßÀѤˤè¤êÓÒÅÇ¡¦Ã¦¿å unknown *
183 Dwarfism
¾®¿Í¾É¡¢Äã¿ÈĹ¾É
¶Ëü¤Ê¾®¤Ö¤ê ¾É¾õ¤Î¤Ò¤È¤Ä¤È¤·¤ÆÄã¿ÈŤò¤­¤¿¤¹ÍÍ¡¹¤Ê¼À´µ¤ò¾®¿Í¾É¤È¸Æ¾Î unknown *
185 Dwarfism, hypochondroplastic
Æð¹üÄã·ÁÀ®¾É¤Ë¤è¤ë¾®¿Í¾É
ÀèÅ·À­¤Î»Í»èû½Ì·¿Äã¿ÈĹ¾É ÊÌ̾¥¢¥¤¥ê¥Ã¥·¥å¥»¥Ã¥¿¡¼¾®¿Í¾É¡£½ÐÀ¸»þ¡ÁÎ¥Æý»þ¤Þ¤Ç¤Îɽ¸½·¿¤ÏÀµ¾ï¤ÇÀ¸¸å2¥ö·îȾ¡Á4¥ö·î¤Þ¤Ç¤ËÇعü¤È»Í»è¤ÎÀ®Ä¹¤¬Ãø¤·¤¯ÃÙ¤ì¤À¤¹¡£1998ǯ¥Î¥ë¥¦¥§¡¼¤Ç¥Æ¥¹¥È¸òÇÛ¤¬¤Ê¤µ¤ì°äÅÁŪ¡¢Î×¾²Åª¡¢·ÁÂַ׬¡¢XÀþ»£±Æ¡¢¹üÁÈ¿¥¤È·ìÞù¤È¾®¿Í¾É¤ÎÇ¢Ãæ¤ÎÀ¸²½³ØŪÆÃħ¤òÄ´¤Ù¤é¤ì¤¿ AR I¥»¥Ã¥¿¡¼
186 Dwarfism, pituitary
²¼¿âÂÎÀ­Äã¿ÈĹ¾É¡¢²¼¿âÂÎÀ­¾®¿Í¾É
Á´¿ÈÀ­È¯°éÉÔÁ´ Genes:LHX3
¿¤¯¤¬À¸¸å6½µ´Ö¤¯¤é¤¤¤«¤éÀ®Ä¹Ãٱ䡢ÂΤÎäÂÀ¤â¤â¤äÈø¤ÎæÌÓ¡¦ÌµÌÓ¡¢Çö¤¤ÈéÉ桦¤¦¤í¤³¾õ¡¢¤æ¤Ã¤¯¤ê¿Ê¤à²áÅ٤ο§ÁÇÄÀÃå¡¢Ä̾ïû̿ °äÅÁ»Ò¸¡ºº¥¢¥ê¡¡¥ª¥é¥ó¥À¥æ¥È¥ì¥Ò¥ÈÂç³Ø¤ÇG¥·¥§¥Ñ¤È¥Á¥§¥³¥¹¥ë¥Ð¥­¥¢¥ó¥¦¥ë¥Õ¥É¥Ã¥°
AR G¥·¥§¥Ñ
200 Ehlers-Danlos syndrome
¥¨¡¼¥é¥¹¡¦¥À¥ó¥í¥¹¾É¸õ·²
ÈéÉæ¤Î²á¿­Å¸¡¢ÀȼåÀ­¡¢·ì¼ð¤¬Ç§¤á¤é¤ì¡¢´Ö»¤Éô¤ÎÁýÂç¤Ë¤è¤êÁßáÚ¤ò¼¨¤¹(Wiki) ¥³¥é¡¼¥²¥óÀþ°Ý·ÁÀ®µ¡¹½¤Î°Û¾ï¤ò¸¶°ø¤È¤¹¤ë¾É¸õ·²¡£ÈéÉæ̵ÎϾɡ¢ÈéÉæÀȼå¾É¡¢²á¾êÃÆÎÏÀ­ÈéÉæ¤È¤â¸Æ¤Ð¤ì¤ë(Wiki) AD *
236 Fucosidosis, alpha
¦Á-¥Õ¥³¥·¥É¡¼¥·¥¹
Àº¿À±¿Æ°È¯Ã£ÃÙÂÚ¡¢¾®¤Ö¤ê¡¢°×´¶À÷À­¡¢Â¿È¯À­¹ü·ÁÀ®ÉÔÁ´¡¢Èï³Ñ·ì´É¼ð¡¢´ØÀá¹´½Ì¡¢¤±¤¤¤ì¤óȯºî¡¢´Î磼ð¡¢ÆñÄ°¡¢¥Ø¥ë¥Ë¥¢¡¢»ëÎϾ㳲 Genes:FUCA1
¦Á-L-¥Õ¥³¥·¥À¡¼¥¼·ç»¤Ë¤è¤ëºÙ˦¥é¥¤¥½¥¾¡¼¥àÆâ¤Ø¤Î¥ª¥ê¥´ÅüÃßÀÑ¡£¥Ò¥È¤Î¾ì¹ç¤Ï2·¿¤Ëʬ¤±¤é¤ì¤ë¤³¤È¤¬Â¿¤¯¿Ê¹Ô¤ÎÁᤤ½Å¾É·¿¤ÈÈï³Ñ·ì´É¼ð¤òȼ¤¦¿Ê¹Ô¤Î´Ë¤ä¤«¤Ê·Ú¾É·¿¤¬ÃΤé¤ì¤ë¡£Èï³Ñ·ì´É¼ð¤È¤ÏɽÌ̤˲á¾ê¤Ê³Ñ²½¤òȼ¤¦·ì´É¼ð¡ÊµÖ¿¾¡Ë¤Î°ì¼ï¤Ç¾¯¤··ì¤Îº®¤¸¤Ã¤¿¤«¤µ¤Ö¤¿¤Î¤è¤¦¤Ë¤·¤«¸«¤¨¤Ê¤¤¤â¤Î¤â¤¢¤ë¡Ê°ìÈÌ»ô¤¤¼ç¤Ç¤¢¤ì¤ÐÌ¿¤¬´í¤¦¤¤Éµ¤¤Ë´Ø·¸À­¤¬¤¢¤ë¤ÈÁÛÁü¤·¤Ë¤¯¤¤¡Ë
AR *
238 Galactosialidosis
¥¬¥é¥¯¥È¡¦¥·¥¢¥ê¥É¡¼¥·¥¹
¹ü¤ÎÊÑ·Á¡¢´Î¡¤äç£Â¡¤Î¼ðÂç¡¢Áͷ¥إë¥Ë¥¢¡¢çÁ¥Ø¥ë¥Ë¥¢¡¢¿´ÉÔÁ´¡¢¿ÕÉÔÁ´¡¢¸ÆµÛ¾ã³²¤äÃæ¿õ¿À·Ð¾ã³²(¥ß¥ª¥¯¥í¡¼¥Ì¥¹¡¢¤±¤¤¤ì¤óȯºî) ¥é¥¤¥½¥¾¡¼¥àÀ­ÊݸîÃÁÇò¼Á/¥«¥Æ¥×¥·¥óA¡ÊPPCA¡Ë¤Î³èÀ­Äã²¼¤Ë¤è¤êÈó´Ô¸µËöü¤Ë¥·¥¢¥ë»À»Ä´ð¤ò»ý¤Ä¥ª¥ê¥´Åü¤äÅüÃÁÇò¼Á¤ª¤è¤ÓÅü»é¼Á¤¬Ê¬²ò¤µ¤ì¤º¤ËºÙ˦Æâ¤ËÃßÀѤ·¤ÆºÙ˦¤¬¾ã³²¤ò¼õ¤±¤ë¡£¥¬¥ó¥°¥ê¥ª¥·¥É¡¼¥·¥¹¤È¾É¾õ¤¬»÷¤ë¤¬¤³¤Á¤é¤Ï¤ä¤ä·Ú¤¤ unknown *
240 Gangliosidosis
¥¬¥ó¥°¥ê¥ª¥·¥É¡¼¥·¥¹
¼ãÎð´ü¤Î±¿Æ°¼ºÄ´¤«¤é»Ï¤Þ¤ê¡¢¤±¤¤¤ì¤óȯºî¡¢»ëÎÏÄã²¼(¼ºÌÀ)¡¢ÃÔÊòÍ;ɾõ¤Ê¤É¤òµ¯¤³¤·Áá´ü»àË´ ¥¬¥ó¥°¥ê¥ª¥·¥É¤Î¥é¥¤¥½¥¾¡¼¥àÃßÀÑÉ¡£»é¼ÁÂå¼Õ²óÏ©Ãæ¤ÎÆÃÄê¤Î¹ÚÁǤη绤ǻé¼Á¤Î°ì¼ï¤Ç¤¢¤ë¥¬¥ó¥°¥ê¥ª¥·¥É¤¬¿À·ÐºÙ˦¤Ê¤É¤Ë°Û¾ï¤ËÃßÀѤ¹¤ë¤³¤È¤Çµ¯¤³¤ë¡£ unknown *
241 Gangliosidosis, GM1
GM1¥¬¥ó¥°¥ê¥ª¥·¥É¡¼¥·¥¹
Ê¢¿å¤ä»Í»è¤ÎÉâ¼ð¡¢¹üÊÑ·Á¡¢¤½¤Î¾¥¬¥ó¥°¥ê¥ª¥·¥É¡¼¥·¥¹»²¾È Genes:GLB1
GM1¥¬¥ó¥°¥ê¥ª¥·¥É¦Â¥¬¥é¥¯¥È¥·¥À¡¼¥¼·ç»¾É¡¢¥é¥¤¥½¥¾¡¼¥àÃßÀÑÉÂ
AR *
242 Gangliosidosis, GM2, generic
GM2¥¬¥ó¥°¥ê¥ª¥·¥É¡¼¥·¥¹
¥¬¥ó¥°¥ê¥ª¥·¥É¡¼¥·¥¹»²¾È ¦Â¥Ø¥­¥½¥µ¥ß¥Ë¥À¡¼¥¼·ç»¾É¡¢¥é¥¤¥½¥¾¡¼¥àÃßÀÑÉ AR *
243 Gangliosidosis, GM2, GM2A deficiency
GM2¥¬¥ó¥°¥ê¥ª¥·¥É¡¼¥·¥¹GM2A·ç»¾É
¥¬¥ó¥°¥ê¥ª¥·¥É¡¼¥·¥¹»²¾È ¥é¥¤¥½¥¾¡¼¥àÃßÀÑÉ AR *
244 Gangliosidosis, GM2, type I(B variant)
¥¬¥ó¥°¥ê¥ª¥·¥É¡¼¥·¥¹GM2­µ·¿
¥¬¥ó¥°¥ê¥ª¥·¥É¡¼¥·¥¹»²¾È Gene: HEXA
¥Æ¥¤¡Ý¥µ¥Ã¥¯¥¹¡ÊTay-Sachs¡ËÉÂ
¥é¥¤¥½¥¾¡¼¥àÃßÀÑÉ¡£¥Ø¥­¥½¥µ¥ß¥Ë¥À¡¼¥¼¹ÚÁǤηçÇ¡¤Ëµ¯°ø¤¹¤ëÍÍ¡¹¤ÊÁÈ¿¥¤Ë¤ª¤±¤ëGM2¥¬¥ó¥°¥ê¥ª¥·¥É¡ÊÅü»é¼Á¤Î°ì¼ï¡Ë¤ÎÃßÀÑ
AR à¾
245 Gangliosidosis, GM2, type II(Sandhoff or variant 0)
¥¬¥ó¥°¥ê¥ª¥·¥É¡¼¥·¥¹GM2­¶·¿
¿Ê¹ÔÀ­¤Î¿À·Ð¶Úµ¡Ç½¾ã³²¡¦À®Ä¹¾ã³² Gene: HEXB
¥é¥¤¥½¥¾¡¼¥àÃßÀÑÉ¡£¥Ø¥­¥½¥µ¥ß¥Ë¥À¡¼¥¼¹ÚÁǤηçÇ¡¤Ëµ¯°ø¤¹¤ëÍÍ¡¹¤ÊÁÈ¿¥¤Ë¤ª¤±¤ëGM2¥¬¥ó¥°¥ê¥ª¥·¥É¡ÊÅü»é¼Á¤Î°ì¼ï¡Ë¤ÎÃßÀÑ¡£
AR ¥È¥¤¥×¡¼¡¢¥´¥ë¡¢Ç­
248 Gaucher disease, type I
¥¿¥¤¥×1¥´¡¼¥·¥§ÉÂ
¼Ð»ë¡¢À®Ä¹Ãٱ䡢¤±¤¤¤ì¤óȯºî¡¢°×¹üÀÞÀ­¡¢´Î磼𡢷쾮ÈĤθº¾¯¡¢ÉÏ·ì ¥°¥ë¥³¥»¥ì¥Ö¥í¥·¥¿¡¼¥¼Äã³èÀ­¤Ë¤è¤ë¥é¥¤¥½¥¾¡¼¥à¼À´µ¡£¥Ò¥È¤Ç¤Ï3·¿¤Ëʬ¤±¤é¤ì¤ë¾ïÀ÷¿§ÂÎÀøÀ­°äÅÁ ñ°ì°äÅÁ»Ò *
262 Glycogen storage disease I
Åü¸¶É­µ·¿
¾®¿©¡¢Äã·ìÅüȯºî(·îÎ𤬿ʤà¤È´ËϤµ¤ì¤ë)¡¢À®Ä¹Ãٱ䡢(É¡¤Ê¤É)½Ð·ì¡¢´Î¼ðÂç(Ê¢ÉôËÄËþ)¡¢¹â»é·ì¾É¡¢¹âÇ¢»À·ì¾É Gene: G6PC
¥Õ¥©¥ó¥®¡¼¥ë¥±¡£glucose-6-phosphatase°Û¾ï¤Ë¤è¤ë´Î¿Õ·¿¥°¥ê¥³¡¼¥²¥óÃßÀѾɡ£Â¿Î̤Υ°¥ê¥³¡¼¥²¥ó¤¬´Î¡¡¦¿Õ¡¤ËÃßÀÑ¡£
AR *
263 Glycogen storage disease ­¶
Åü¸¶É­¶·¿
½é´ü¤ÏÉÔ̲¤È±¿Æ°»þ¤Î¸ÆµÛº¤Æñ¤ò´Þ¤à¶ÚÎÏÄã²¼¡¢´Î¡¦¿´¼ðÂç¡¢¿´ÉÔÁ´¤ÇÁá´ü»àË´ ¥Ý¥ó¥ÚÉÂ(¥Ý¥ó¥Ú¤Ïȯ¸«¤·¤¿¥ª¥é¥ó¥À¤Î°å»Õ¤Î̾)¡£»ÀÀ­¥Þ¥ë¥¿¡¼¥¼(a-¥°¥ë¥³¥·¥¿¡¼¥¼¤È¤â¸À¤¦)·ç»¤Ë¤è¤ë¥°¥ê¥³¡¼¥²¥óÃßÀÑ¾É ¾ïÀ÷¿§ÂÎÀ­¡¢Ã±°ì°äÅÁ»Ò *
264 Glycogen storage disease IIIa
Åü¸¶ÉÂIIIa·¿
´Î¼ðÂç¡¢¶ÚÎÏÄã²¼ Gene: AGL
¥³¥êÉÂ
AR *
265 Glycogen storage disease ­»
Åü¸¶É­»·¿
±¿Æ°Ãæ¤Î¶ÚÄË(¤¿¤À¤·°ìµÙ¤ß¸å¤Ë¤Ï±¿Æ°Á°¤ËÌá¤ë¤Î¤ÇµÙ·Æ¤òÆþ¤ì¤ì¤Ð³¹Ô¤Ç¤­¤ë)¡¢°×ÈèÏ«¡¢¶Ú¶¯Ä¾¡£±¿Æ°¸å¤Î¥ß¥ª¥°¥í¥Ó¥óÇ¢(Èó¾ï¤ËÇ»¤¤¿§)¡£ÍÏ·ì·¹¸þ¡¢¹â¥Ó¥ê¥ë¥Ó¥ó·ì¾É¡£·ìÀ­¥¯¥ì¥¢¥Á¥ó¥­¥Ê¡¼¥¼(CPK)¤Î¾å¾º¡£ Genes:PFKM
¿â°æÉÂ(ºÇ½é¤Ëɵ¤¤ÎÊó¹ð¤ò¤·¤¿¿â°æÂçºåÂç³Ø̾ÍÀ¶µ¼ø¤Ë°ø¤à)¡£¶Ú¥Û¥¹¥Û¥Õ¥ë¥¯¥È¥­¥Ê¡¼¥¼·ç»¤Ë¤è¤ë¥ß¥ª¥Ñ¥Á¡¼
AR *
266 Goitre, familial
²È²À­¹Ã¾õÁ£¼ð
¹Ã¾õÁ£¤Î³ÈÂç¡¢¼ó¤ÎÁ°¤Î¼ð¤ì ¹Ã¾õÁ£¼ð¤È¤Ï¹Ã¾õÁ£µ¡Ç½¤Î°Û¾ï¤¬´ØÏ¢¤·¤Æ¤¤¤ë¤¤¤Ê¤¤¤Ë´Ø¤ï¤é¤º¹Ã¾õÁ£¤¬³ÈÂ礵¤ì¤¿¾õÂÖ¤ÎÁí¾Î¡£

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3395427/ ¹Ã¾õÁ£Âå¼Õ¤Î¸¶È¯À­ÀèÅ·°Û¾ï¤È·ì´Éȯã²áÄø¤Î·ç´Ù¤Î´ØÏ¢À­2012ǯ¤Î»¨»ïJournal of the American Animal Hospital Association¡ÊVol. 48¡Ë¤Ë¸ø³«¤µ¤ì¤¿¸¦µæ ¡ÊÀ¸¸å4¡Á5¥õ·îÎð¤Î¥ê¥Ã¥¿¡¼8Ƭ¤Î¤¦¤Á3Ƭ¤Î»Ò¸¤¤ÎÊ¢Éô»ÒµÜðôÉôÎΰè¤Ëǧ¤á¤é¤ì¤¿Î¾Â¦Èé²¼¼ðáî¤Î³Æ¼ï¸¡ºº·ë²Ì¡Ë
¹Ã¾õÁ£¥Û¥ë¥â¥ó¤Î·ìÀ¶Ç»ÅÙ¤¬´ð½àÈÏ°Ï̤Ëþ¤Ç¤¢¤Ã¤¿¡¢ÂçÉôʬ¤¬Á£¤ÎÎΰè¤Ë½ÅÅ٤˳ÈÄ¥¤·¤¿°Û¾ï¤ÊÌ®´É¹½Â¤¤òÍ­¤¹¤ë³ÈÂç¹Ã¾õÁ£¤ÈƱÄꤵ¤ì¤¿¡¢¹Ã¾õÁ£¼ð¤Î¸ºß¤ò½ü¤¤¤Æ¡¢¹Ã¾õÁ£µ¡Ç½Äã²¼¾É¤ÎÎ×¾²Ä§¸õ¤ò¼¨¤µ¤Ê¤«¤Ã¤¿¡¢1Ƭ¤ÏÆ°Ì®´É³«Â¸¾É¤òʻȯ¡¢¤Û¤«
unknown PL¥·¡¼¥×¥É¥Ã¥°
Hyperadrenocorticism
Éû¿ÕÈé¼Áµ¡Ç½Ð¶¿Ê¾É
½é´ü¤Ï¿©Íߤä°û¿åÎ̤äÇ¢Î̤ÎÁý²Ã¡¢Ê¢ÉôËÄËþ¡¢º¸±¦ÂоݤÇáڤߤΤʤ¤Ã¦ÌÓ¤Ê¤É ¥¯¥Ã¥·¥ó¥°¾É¸õ·²¡¢ÈéÉ濭ŸÀþ¾ò(¥Ò¥È¤ÎÇ¥¿±Àþ¤Î¤è¤¦¤Ê¤â¤Î)¤äÈéÉ椬Àȼå¤Ë¤Ê¤ë¤³¤È¤â¤¢¤ë¡£¢ÎÉû¿ÕÈé¼Áµ¡Ç½Äã²¼¥¢¥¸¥½¥óÉÂ(³°½ýÉô°Ì¤Ë¿§ÁÇÁý²Ã¤¬ÌÜΩ¤Ä)
Dr. ¾®µÜ»³¤Îȼηưʪ¤Ø¤Î¤ä¤µ¤·¤¤¡ÊÍ¥¤·¤¤¡Ë½Ã°å³Ø¡Ö¸¤¤ÎÉû¿ÕÈé¼Áµ¡Ç½Ð¶¿Ê¾É¡Ê¸¤¤Î¥¯¥Ã¥·¥ó¥°¾É¸õ·²¡Ë (2005/5/14 ÂèÆó²ó²þÄû)¡×
* *
317 Hypercholesterolaemia
¹â¥³¥ì¥¹¥Æ¥í¡¼¥ë·ì¾É
ÌܤΥեÁ¤ä¤Þ¤Ö¤¿¤ÎÆ⦴ޤàÌܤμþ°Ï¤Ë¾®¤µ¤¤»éËäΤǤ­¤â¤Î¡¢Æ°Ì®¶¹ºõ¡¢Æ°Ì®¹Å²½¡¢µõ·ìÀ­¿´¼À´µ¡Ê¶¹¿´¾É¡¢¿´¶Ú¹¼ºÉ¡Ë ·ì±ÕÃæ¤ÎÁí¥³¥ì¥¹¥Æ¥í¡¼¥ëÃͤ¬¹â¤¤¥¿¥¤¥×¤Î»é¼Á°Û¾ï¾É¤Ç¤¤¤¯¤Ä¤«¤Î·¿¤¬¤¢¤ë¤¬ÂÎÆâ¤Î¥³¥ì¥¹¥Æ¥í¡¼¥ë¤ò±¿¤Ö¤¿¤á¤Î¼õÍÆÂΤäʬ²ò¹ÚÁǤη绤¬¼ç¡£¥¢¥­¥ì¥¹ç§¤Ë¤â»éËü𤬤Ǥ­¤¿¤ê¤½¤Î¼þ°Ï¤¬¼ð¤ì¤¿¤è¤¦¤ËÈî¸ü¤¹¤ë¾ì¹ç¤â¤¢¤ë¡£ Æ°Ì®¹Å²½¤Ê¤É¤Ë¤è¤ê¿´Â¡¤Ë¤Ï¤ê¤á¤°¤é¤µ¤ì¤¿´§Æ°Ì®¤Ë½½Ê¬¤Ê»ÀÁÇ¡¦¥¨¥Í¥ë¥®¡¼¤¬¹Ô¤­ÅϤé¤Ê¤¤¾õÂÖ¤òµõ·ì¤È¤¤¤¤¡¢ µõ·ì¤¬°ì²áÀ­¤À¤È¶¹¿´¾É¡¢´§Æ°Ì®¤¬´°Á´¤ËµÍ¤Þ¤ê¿´¶Ú¤¬²õ»à¤¹¤ë¤È¿´¶Ú¹¼ºÉ¡£¹Ã¾õÁ£µ¡Ç½Äã²¼¾É¡¢ÅüǢɡ¢¥Í¥Õ¥í¡¼¥¼¾É¸õ·²¡¢ÊĺÉÀ­²«áդʤɤǤâ·ìÀ¶¥³¥ì¥¹¥Æ¥í¡¼¥ëÃͤϾ徺¤¹¤ë¡ÊÆó¼¡À­¡Ë * ¥É¡¼¥Ù¥ë¥Þ¥ó¡¢¥í¥Ã¥È¥ï¥¤¥é¡¼¡¢¥³¥ê¡¼
325 Hyperlipidaemia
¹â»é·ì¾É
Áê±þ¤Ë¿Ê¹Ô¤¹¤ë¤Þ¤Ç¾É¾õ¤¬¤Û¤È¤ó¤É̵¤¤¡£ç¹±ê¤ä¿´¶Ú¹¼ºÉ¤Ë»ê¤ë¤³¤È¤â¤¢¤ë¡£ ·ìÃæ»é¼ÁÃͤ¬°Û¾ï¤Ë¿¤¤¾õÂÖ¡£»é¼Á°Û¾ï¾Édyslipidemia¤ò°ÊÁ°¤Ï¹â»é·ì¾É¤È¸À¤Ã¤¿¡£ unknown *
326 Hyperlipoproteinaemia
¹â¥ê¥ÝÃÁÇò·ì¾É
¹â»é·ì¾É¤ÈƱÍÍ¡¢´Î¼ð¡¢ç£¼ð¡¢·«¤êÊÖ¤¹Ê¢ÄËȯºî ¥Ò¥È¤Ç¤Ï²«¿§¼ð¤¬¤Þ¤Ö¤¿¤äɪ¡¦É¨¡¦¿¬¡¦ÇØÃ桦µÓ¤ÎÁ°Â¦¡¢ÏӤθ妤ʤɤ˽ÐÍè¤ë¡£ç¹±ê¡£»à¤Ë»ê¤ë¤³¤È¤â¤¢¤ë¡£
¥ê¥ÝÃÁÇò¤Ï»é¼Á¤¬·ìÞùÃæ¤Ë¸ºß¤¹¤ëÍÍÂ֤ǡ¢»é¼Á¤È¥¢¥Ý¥ê¥Ý¥¿¥ó¥Ñ¥¯¼Á¤¬·ë¹ç¤·¤¿¤â¤Î
unknown M¥·¥å¥Ê
327 Hyperparathyroidism
Éû¹Ã¾õÁ£µ¡Ç½Ð¶¿Ê¾É
¸µµ¤¾ÃÄÀ¡¢¿Õ·ëÀС¢¿©ÍßÉÔ¿¶¡¦ÓÒÅÇ¡¦²¼Î¡(¾Ã²½À­ÄÙáç)¡¢ç¹±ê¡¢°×¹üÀÞÀ­ ·ì±ÕÃæ¤Î¥«¥ë¥·¥¦¥àÇ»ÅÙ¤ò°ìÄê¤ÎÈÏ°ÏÆâ¤ËÄ´À᤹¤ëÉû¹Ã¾õÁ£¥Û¥ë¥â¥ó¤¬¾åÈé¾®ÂΤβá·ÁÀ®¤äÁ£¼ð¤¬¼ç¤Ê¸¶°ø¤Ç¡¢·ì±ÕÃæ¤Î¥«¥ë¥·¥¦¥à¤¬Àµ¾ï¤Þ¤¿¤Ï¤½¤ì°Ê¾å¤¢¤ë¤Î¤ËÉû¹Ã¾õÁ£¥Û¥ë¥â¥ó¤¬É¬Íװʾå¤Ë¤Ä¤¯¤é¤ì¤ë¤³¤È¤Çµ¯¤³¤ëɵ¤¡£
·ò¹¯ÂΤǤϷì±ÕÃæ¤Î¥«¥ë¥·¥¦¥à¤¬¸º¤ë¤ÈÉû¹Ã¾õÁ£¥Û¥ë¥â¥ó¤¬Áý²Ã¤¹¤ë¤³¤È¤Ë¤è¤ê¹ü¤ËÃߤ¨¤é¤ì¤Æ¤¤¤ë¥«¥ë¥·¥¦¥à¤¬·ì±ÕÃæ¤ËÍϤ«¤·½Ð¤µ¤ì¤Æ¥«¥ë¥·¥¦¥àÇ»ÅÙ¤¬Àµ¾ï¤ËÌá¤ë»ÅÁȤߤˤʤäƤ¤¤ë¡£
¿ÇÃÇ;¹â¢ª·ìÃ楫¥ë¥·¥¦¥àÇ»ÅÙ¤ÈÉû¹Ã¾õÁ£¥Û¥ë¥â¥ó¤ÈÇ¢Ã楫¥ë¥·¥¦¥àÇÓÝõÎÌ
AD ¿
328 Hyperphosphatasaemia
¹â¥¢¥ë¥«¥ê¥Û¥¹¥Õ¥¡¥¿¡¼¥¼·ì¾É
̵¾É¾õ¤Þ¤¿¤ÏÓÒÅǤ䲼Ρ¤Ê¤É·Ú¤¤¾Ã²½´ï¾É¾õ ¥¢¥ë¥«¥ê¥Û¥¹¥Õ¥¡¥¿¡¼¥¼(ALP¡á´Îµ¡Ç½¤Î»Øɸ¤Î¤Ò¤È¤Ä)¤È¤Ï¥¢¥ë¥«¥êÀ­¤Î¾õ¶·²¼¤Ç¥ê¥ó»À¥¨¥¹¥Æ¥ë²½¹çʪ¤ò²Ã¿åʬ²ò¤¹¤ë¹ÚÁÇ¡£´Î¡¡¢¿Õ¡¡¢¹ü¡¢¾®Ä²¡¢ÂÛÈפʤɤË¿¤¯´Þ¤Þ¤ì¤ë¤Î¤Ç¤½¤ì¤é¤Î¡´ï¤¬¥À¥á¡¼¥¸¤ò¼õ¤±¤ë¤È·ì±ÕÃæ¤Ç¹âÃͤȤʤ롣¤¬¡¢²È²À­ÎÉÀ­¹â¥¢¥ë¥«¥ê¥Û¥¹¥Õ¥¡¥¿¡¼¥¼·ì¾É¤Ç¤Ï¡¢Î×¾²¡¢Êü¼ÍÀþ³ØŪ¡¢À¸²½³ØŪɾ²Á¤Ï¾¤Î°Û¾ï½ê¸«¤òǧ¤á¤Ê¤¤¤Î¤Ë·ìÀ¶¥¢¥ë¥«¥êÀ­¥Û¥¹¥Õ¥¡¥¿¡¼¥¼¡ÊALP¡Ë¤ÎñÆȹâÃ͡ʾ®Ä²·¿ALP¤ËͳÍ褹¤ë·ìÀ¶ALP¤Î°Û¾ï¹âÃ͡ˤ¬¸«¤é¤ì¤ë¡¢¤È¤¤¤¦¸¦µæ unknown ¥Ï¥¹¥­¡¼
331 Hypertrichosis
¿ÌÓ¾É
¿Ë¶â¾õ¡¢ÍÓÌÓ¾õ¡¢ÇȾõ¤Ê¤É¤ÎÆÈÆäʰ۾ï¤Ê¥³¡¼¥È 1¤Ä¤ÎÌÓÊñ¤«¤éÊ£¿ô¤ÎÌÓ¤¬È¯À¸¤¹¤ë¡£¤³¤Î°Û¾ï¤Ï¹¶·âÀ­¤ä¿ư¡¦³Ø½¬¾ã³²¤òȼ¤¤¤·¤Ð¤·¤ÐÌ©Àܤ˿åƬ¾É¤äÃæ¿õ¿À·Ð·Ï¤Ë±Æ¶Á¤òÍ¿¤¨¤ëɵ¤¤Ë´ØÏ¢ÉÕ¤±¤é¤ì¤Æ¤¤¤ë unknown ¥´¥ë
332 Hypertriglyceridaemia
¹â¥È¥ê¥°¥ê¥»¥ê¥É·ì¾É
°­²½¤·¤Æ¤«¤é¤Î¿©ÍßÉÔ¿¶¡¢¾Ã²½´ï¾É¾õ¡¢ç¹±ê ·ì±ÕÃæ¤Ë´Þ¤Þ¤ì¤ë»é¼Á¤¬²á¾ê¤¢¤ë¤¤¤ÏÉÔ­¤¹¤ë»é¼Á°Û¾ï¾É(°ÊÁ°¤Ï¹â»é·ì¾É¤È¸Æ¤ó¤À)¤Î¤¦¤Á·ì±ÕÃæ¤ËÃæÀ­»éËÃ(¥È¥ê¥°¥ê¥»¥ê¥É)¤¬Â¿¤¯Â¸ºß¤¹¤ë¥¿¥¤¥×¤Î»é¼Á°Û¾ï¾É¡£¥ß¥Ë¥·¥å¥Ê¤Î¾ì¹ç¤Ï¥¤¥ó¥¹¥ê¥óÄñ¹³À­¤È´ØÏ¢¤·¤Æ¤¤¤ë unknown M¥·¥å¥Ê
333 Hypoadrenocorticism
Éû¿ÕÈé¼Áµ¡Ç½Äã²¼¾É
¿°û¡¢¿©ÍßÉÔ¿¶¡¢¿´Çï¿ôÄã²¼¡¢ÄãÂβ¹¡¢¿Ì¤¨¡¢²¼Î¡¡¢ÓÒÅÇ¡¢ÂνŸº¾¯ Éû¿Õ¤«¤éʬÈ礵¤ì¤ë¥Û¥ë¥â¥ó¤Î·ç˳¡¢¥¢¥¸¥½¥óÉ unknown ¥´¥ë¡¢¥Ó¥¢¥Ç¥£¡¢G¥·¥§¥Ñ
334 Hypoadrenocorticism, primary
¸¶È¯À­Éû¿ÕÈé¼ÁÄã·ÁÀ®
¿©ÍßÉÔ¿¶¡¢¶ÚÎÏÄã²¼¡¢Ìµµ¤ÎÏ ¸¶È¯À­¤È¤ÏºÇ½é¤Ë¤½¤ÎÉô°Ì¤Ëȯ¾É¤¹¤ë¡¢¤È¤¤¤Ã¤¿°ÕÌ£¡£¢ÎÆó¼¡À­¡£¸¶È¯À­¤ÎËýÀ­Éû¿ÕÈé¼Áµ¡Ç½Äã²¼¾É¤Ë¤ÏÀèÅ·À­¤Î¤â¤Î¤È¸åÅ·À­¤Î¤â¤Î¤¬Â¸ºß¤·¡¢ÀèÅ·À­¤Î¤â¤Î¤Ï¥¢¥¸¥½¥óɤȤÏÆÈΩ¤·¤¿¼À´µÃ±°Ì¤È¤·¤Æ°·¤ï¤ì¤ë¤è¤¦¤Ë¤Ê¤Ã¤¿¡£¤³¤Î¤¿¤á¡¢¥¢¥¸¥½¥óɤϸåÅ·À­¤ÎÀ®°ø¤Ë¤è¤ëÉÂÂÖ¤òÁí¾Î¤¹¤ëÍѸì¤È¤·¤ÆÍѤ¤¤é¤ì¤Æ¤¤¤ë unknown ¿
335 Hypocatalasia
Ä㥫¥¿¥é¡¼¥¼¾É
»õ¼þ°ÏÁÈ¿¥¤Î¿Ê¹ÔÀ­²õáÔÀ­ÉÂÊÑ ÀèÅ·À­¤Î°äÅÁŪ¹ÚÁǷ绤ÎÂåɽÎã¡£ÂÎÆâÃæ¤Î¥«¥¿¥é¡¼¥¼¤¬ÉÔ­¤·¡¢²á»À²½¿åÁǤ¬Ê¬²ò¤Ç¤­¤Ê¤¯¤Ê¤ëɵ¤¡£¹â¸¶»áÉÂ(Takahara's disease)¡£Ìµ¥«¥¿¥é¡¼¥¼¾É¤ÏAcatalasia ñ°ì°äÅÁ»Ò
¤ª¤½¤é¤¯AR
¥Ó¡¼¥°¥ë
337 Hypolipoproteinaemia
Äã¥ê¥ÝÃÁÇò·ì¾É
̵¾É¾õ¤«¤é»éËää»éÍÏÀ­¥Ó¥¿¥ß¥óE¡¢K¡¢AµÛ¼ý¾ã³²¤Ë¤è¤ë²¼Î¡¡¢¾®¤Ö¤ê¡¢Î®»º¡¢¹â·ì°µ¡¢Ç¾Â´Ãæ¡¢ÆÍÁ³»à ¹â»é·ì¾É¡£Áí¥³¥ì¥¹¥Æ¥í¡¼¥ë¹âÃÍ unknown M¥·¥å¥Ê
340 Hypoparathyroidism
Éû¹Ã¾õÁ£µ¡Ç½Äã²¼¾É¡¢¾åÈé¾®ÂÎÄã²¼¾É
¥Æ¥¿¥Ë¡¼(»Í»è¤Îáã¤ì)¡¢¤±¤¤¤ì¤óȯºî¡¢Êâ¹Ô°Û¾ï Éû¹Ã¾õÁ£¥Û¥ë¥â¥ó(PTH)¤ÎÉÔ­¤ò¸¶°ø¤È¤·¤¿Ä㥫¥ë¥·¥¦¥à·ì¾É¡¢¹â¥ê¥ó·ì¾É¤Ë¤è¤Ã¤Æ¼ï¡¹¤Î¾É¾õ¤ò¼¨¤¹Âå¼ÕÀ­¼À´µ * *
343 Hypothyroidism
¹Ã¾õÁ£µ¡Ç½Äã²¼¾É
¸µµ¤¾ÃÄÀ¡¢ÂνÅÁý²Ã¡¢¹¶·âÀ­¡¢Êâ¹Ô»þ¤Î¤³¤ï¤Ð¤ê¡¢º¸±¦ÂоÎÀ­Ã¦ÌÓ¡¢¤Æ¤ó¤«¤óȯºî¡¢Ç´±Õ¿å¼ð Genes:TPO
Á´¿È¤Î¥¨¥Í¥ë¥®¡¼ÍøÍѤòÂ¥¤¹¹Ã¾õÁ£¥Û¥ë¥â¥ó¤ÎʬÈçÎÌ(³èÀ­)¤¬ÉÔ½½Ê¬¤È¤Ê¤ëÆâʬÈç¼À´µ¡£¤è¤Ã¤Æ¾É¾õ¤Ë¤«¤Ê¤ê¸ÄÂκ¹¤¬¤¢¤ë¡£¹Ã¾õÁ£¼«ÂΤÎÌäÂê¤Ë¤è¤ëʬÈçÉÔÁ´¤Ï¸¶È¯À­¹Ã¾õÁ£µ¡Ç½Äã²¼¾É¡¢¹Ã¾õÁ£»É·ã¥Û¥ë¥â¥ó(TSH)ÉÔ­¤Ë¤è¤ëʬÈçÉÔÁ´¤ÏÆó¼¡À­¹Ã¾õÁ£µ¡Ç½Äã²¼¾É¡¢¹Ã¾õÁ£»É·ã¥Û¥ë¥â¥óÊü½Ð¥Û¥ë¥â¥ó(TRH)¤ÎÄã²¼¤Ë¤è¤ëTSH¤È¹Ã¾õÁ£¥Û¥ë¥â¥ó¤ÎʬÈçÉÔÁ´¤ò»°¼¡À­¹Ã¾õÁ£¥Û¥ë¥â¥óÄã²¼¾É¤È¸Æ¤Ö
AR ¿
344 Hypothyroidism , primary
¸¶È¯À­¹Ã¾õÁ£µ¡Ç½Äã²¼¾É
Ʊ¾å ¼«¸ÊÌȱ־㳲¤Ë¤è¤Ã¤Æ¹Ã¾õÁ£¤¬¹¶·â¤µ¤ì¤ë¥Ò¥È¤Î¶¶ËÜɤǤϹþõÁ£¤ÎËýÀ­±ê¾É¤«¤éµ¡Ç½Äã²¼¤Ë¤¤¤¿¤ê¡¢¥è¥¦ÁÇÉÔ­¤Ç¥Û¥ë¥â¥ó»ºÀ¸¤¬³²¤µ¤ì¤ë¤Ê¤É¤¬¸¶È¯À­¡£¹Ã¾õÁ£¤Îµ¡Ç½¤Ï¼ç¤Ë»ë¾²²¼Éô-²¼¿âÂÎ-¹Ã¾õÁ£·Ï¤¬Àµ¾ï¤Ç¤Ê¤±¤ì¤Ð¤Ê¤é¤Ê¤¯¡¢²¼¿âÂΤμðáç¤ä·ì´É¾ã³²¤Ê¤É¤¬Æó¼¡À­¡¢»°¼¡À­¤ÎÄã²¼¾É¤Ë¤Ä¤Ê¤¬¤ë unknown *
345 Hypotrichosis
ÉÏÌӾɡ¢Ë³ÌÓ¾É
°Ê²¼¤Î¸¤¼ï¤Ç̵ÌÓ¤Ïñ°ì°äÅÁ»ÒºÂ¤Î¥Ø¥Æ¥íÀܹç¤Ç¤¢¤ë ¥Á¥ã¥¤¥Ë¡¼¥º¥¯¥ì¥¹¥Æ¥Ã¥É¥É¥Ã¥°¡¢¥á¥­¥·¥«¥ó¥Ø¥¢¥ì¥¹¥É¥Ã¥°¡¢¥Ú¥ë¡¼¥Ó¥¢¥ó¥Ø¥¢¥ì¥¹¥É¥Ã¥°¤Ê¤É¸²À­¥Ø¥¢¥ì¥¹¼ï¤Î̵ÌÓ ¾ïÀ÷¿§ÂÎÀ­ ¸²À­¥Ø¥¢¥ì¥¹
346 Hypotrichosis, recessive
ÎôÀ­ÉÏÌӾɡ¢Ë³ÌÓ¾É
°Ê²¼¤Î¸¤¼ï¤Ç̵ÌÓ¤Ïñ°ì°äÅÁ»ÒºÂ¤Î¥Û¥âÀܹç¤Ç¤¢¤ë Gene: SGK3
¥¢¥á¥ê¥«¥ó¤Ø¥¢¥ì¥¹¥Æ¥ê¥¢¡Ê¥é¥Ã¥È¥Æ¥ê¥¢¤ÎÆÍÁ³ÊÑ°Û¸ÄÂΡˡ££³Âç̵ÌÓ¼ï¤È¤Ï°Û¤Ê¤ë¾ïÀ÷¿§ÂÎÀøÀ­¥Ø¥¢¥ì¥¹
AR ÀøÀ­¥Ø¥¢¥ì¥¹
358 Inborn error of hepatic metabolism
*´ÎÀ­ÀèÅ·À­Âå¼Õ°Û¾ï
¾ã³²¤Î¤¢¤ëʪ¼Á¤Ë¤è¤ë ÀèÅ·À­Âå¼Õ°Û¾ï¤Î¼£ÎŤΤ¿¤á¤Î°Û·¿´Î°Ü¿¢¤Î¸¦µæ unknown *
372 Krabbe disease
¥¯¥é¥Ã¥ÙÉÂ
´Ë¤ä¤«¤Ê¿Ê¹ÔÀ­¤Î¿Ì¤¨¡¢±¿Æ°¼ºÄ´¡¢Ëãáã¡¢¾®Ç¾µ¡Ç½¾ã³² Genes:GALC
¥é¥¤¥½¥¾¡¼¥à¼À´µ(¥¹¥Õ¥£¥ó¥´»é¼Á¾É)¡£¾ïÀ÷¿§ÂÎÎôÀ­°äÅÁ¤Îæ¿ñÀ­¿À·ÐÊÑÀ­¼À´µ¡¢µåÍͺÙ˦Çò¼Á°à½Ì¾É
AR ¥¦¥§¥¹¥Æ¥£¡¢¥±¥¢¥ó¡¢I¥»¥Ã¥¿¡¼¡¢¥±¥ë¥Ô¡¼¡¢¥À¥ë¥á¥·¥¢¥ó
373 L-2-hydroxyglutaricacidemia
?L-2-¥Ò¥É¥í¥­¥ª¥­¥·¥°¥ë¥¿¥ë»ÀÇ¢¾É
Àº¿À±¿Æ°È¯Ã£ÃÙÂÚ¡¢¤±¤¤¤ì¤óȯºî¡¢±¿Æ°¼ºÄ´¡¢ÃÔÊò Genes: L2HGDH
ÀèÅ·À­Âå¼Õ°Û¾ï¡¢Ç¢ÃæÍ­µ¡»À°Û¾ï(Ç¢¤ä·ì±Õ¤Ê¤ÉL-2-¥Ò¥É¥í¥­¥ª¥­¥·¥°¥ë¥¿¥ë»À¤Î¾å¾º)¡£¼ç¤ËÂçǾÈé¼Á¡¢»ë¾²¡¢¾®Ç¾¡¢Ç¾´´¤Î³¥Çò¼Á¤¬³¤Ìʾõ¤ËÊѲ½¤¹¤ë
AR ¥¹¥¿¥Ã¥Õ¥£¡¼¡¢¥¦¥§¥¹¥Æ¥£
381 Leucodystrophy
Çò¼Á¥¸¥¹¥È¥í¥Õ¥£
¿åƬ¾É¡¢Ç¾ÀÔ¿ñ¤Î¿À·Ð¾É¾õ Gene: CYTB
³¤ÌʾõÊÑÀ­·¿Çò¼Á¥¸¥¹¥È¥í¥Õ¥£ ¡¢¥í¥¤¥³¥¸¥¹¥È¥í¥Õ¥£¡¢Ç¾Çò¼ÁÊÑÀ­¾É¡¢³¤ÌÊǾÀÔ¿ñ¾É¡£¤ª¤½¤é¤¯¥Ò¥È¤Î¥«¥Ê¥Ð¥óÉÂCanavan disease¤Ë¶á¤¤¾É¾õ¤Î¤è¤¦¤À¡£ ǾÀÔ¿ñ¤ÎÇò¼Á¤Ë¹­ÈϰϡʤӤޤóÀ­¡Ë¤Ê½ÅÅ٤γ¤ÌʾõÊÑÀ­¤¬¸«¤é¤ì¤ë¡£Áá´üȯ¾É¡¦Í½¸åÉÔÎÉ
¥ß¥È¥³¥ó¥É¥ê¥¢°äÅÁ ¥À¥ë¡¢¥·¥§¥ë¥Æ¥£
388 Lipidosis
¥ê¥Ô¥É¡¼¥·¥¹
ÌÓ¿§¤Î漺¡¢¤«¤¿¤Þ¤Ã¤¿È´¤±ÌÓ¡¢ÁƤ¤¥ª¡¼¥Ð¡¼¥³¡¼¥È¤ÎÁÓ¼º¡¢ÈéÉæ¤Î¹õ¤º¤ß¡¢À®Ä¹ÉÔÎÉ¡¢¸¶°øÉÔÌÀ¤ÎÓÒÅǤ¬Â¿¤¤ »é¼ÁÂå¼Õ°Û¾ï¡£»é¼Á¡Êlipid)¤¬°Û¾ïÃßÀÑ¡Êosis)¤¹¤ëɵ¤¤ÎÁí¾Î¡£¥é¥¤¥½¥¾¡¼¥àÉÂ(GM£±¥¬¥ó¥°¥ê¥ª¥·¥É¡¼¥·¥¹¡¢¥´¡¼¥·¥§É¡¢¥¯¥é¥Ã¥ÙɤʤÉ)¡£ ¤³¤Î¹àÌܤǤÏLipidosis, follicular ßÉ˦À­¥ê¥Ô¥É¡¼¥·¥¹(ÌÓÊñÆâ¤Ë»éËä¬ÃßÀÑ)¤ÎÀâÌÀ¤Î¤è¤¦¤À unknown *
397 Lysosomal storage disease
¥é¥¤¥½¥¾¡¼¥àÃßÀÑÉÂ
·ç»¹ÚÁǤˤè¤Ã¤Æ¾É¾õ¤Ï¤µ¤Þ¤¶¤Þ ¥é¥¤¥½¥¾¡¼¥à¡ÊºÙ˦Æâ¾®´ï´±¡Ë¤Ë´ØÏ¢¤¹¤ë¹ÚÁǤη绤ˤè¤êʬ²ò¤µ¤ì¤ë¤Ù¤­Êª¼Á¤¬Ï·ÇÑʪ¤È¤·¤ÆÂÎÆâ¤ËÃßÀѤµ¤ì¤ëÂå¼Õ°Û¾ï¾É¤ÎÁí¾Î¡£¥ê¥½¥½¡¼¥à unknown *
409 Menkes syndrome
¥á¥ó¥±¥¹ÉÂ
ȯãÃٱ䡢ÄãÂβ¹¡¢¤±¤¤¤ì¤óȯºî¡¢¶ÚÎÏÄã²¼¡¢½ÌÌÓ Genes:TP53,APRT,CKM,PKLR,CSF1R,ATP7A
XÀ÷¿§ÂÎÏ¢º¿ÎôÀ­°äÅÁ¤Ë¤è¤ëƼÂå¼Õ°Û¾ï¾É
XR *
410 Metabolizer of a congitive enhancer
???Ìô¤ÎÂå¼ÕǽÎÏ
* Gene: CYP1A2
¥¿¥ó¥Ñ¥¯·ç»¾É¤Î¤³¤È¤Î¤è¤¦¤À¡£Ç§ÃÎÁý¶¯ºÞAC-3933¤òÂå¼Õ¤¹¤ëǽÎϤο·¿¤ÎÊó¹ð
unknown ¥Ó¡¼¥°¥ë
418 Mucopolysaccharidosis I
¥à¥³Â¿Åü¾É­µ·¿
¥à¥³Â¿Åü¾É»²¾È Gene: FGFRL1
6¥ö·î¤«¤é1ºÐ¤Çȯ¾É¡£ ¦Á-L-iduronidase·ç»¤Ë¤è¤ë¥Ç¥ë¥Þ¥¿¥óβ»À¤È¥Ø¥Ñ¥é¥óβ»À¤ÎÃßÀÑ¡£­µ·¿¤Ï¤µ¤é¤Ë½Å¾É·¿¤Î¥Ï¡¼¥é¡¼¾É¸õ·²Hurler syndrome¡¢Ãæ´Ö·¿¤Î¥Ï¡¼¥é¡¼-¥·¥ã¥¤¥¨¾É¸õ·²Hurler-Scheie syndrome¡¢·Ú¾É·¿¤Î¥·¥ã¥¤¥¨¾É¸õ·² Scheie syndrome¤ËʬÎव¤ì¤ë¡£
AR *
419 Mucopolysaccharidosis ­¶
¥à¥³Â¿Åü¾É­¶·¿
Àå¤ÎÈîÂç¡¢Áû²»¸ÆµÛ¡¢µ¤Æ»´¶À÷¡¢´Î磼𡢹üÊѲ½¡¢¤Ä¤Þ¤Å¤­¡¢»Í»è¤ò¸ØÄ¥¤¹¤ë¤è¤¦¤ÊÊ⤭Êý¡¢³ÑË캮Âù¡¢´ØÀá¤Î²ÄÆ°À­Äã²¼(¤¹¤Ù¤Æ¿Ê¹ÔÀ­) iduronate-2-sulfatase·ç»¤Ë¤è¤ë¥Ø¥Ñ¥é¥óβ»À¤È¥Ç¥ë¥Þ¥¿¥óβ»À¤ÎÃßÀÑ¡£Ç¢Ãæ¤Ë¥à¥³Â¿Åü¤Ç¤¢¤ë¥Ç¥ë¥Þ¥¿¥óβ»À¡¢¥Ø¥Ñ¥é¥óβ»À¤¬Â¿Î̤ËÇÓÝõ¤µ¤ì¤ë¡£¥Ï¥ó¥¿¡¼¾É¸õ·²Hunter syndrome x-linked *
420 Mucopolysaccharidosis ­·A
¥à¥³Â¿Åü¾É­·A·¿
¿ç̲¾ã³²¡¢È¯Ã£Ãٱ䡢¤±¤¤¤ì¤óȯºî¡¢¶½Ê³¡¢¹¶·âÀ­¡¢Êâ¹ÔÉÔǽ Genes:SGSH
·ç»¹ÚÁǤΰ㤤¤Ë¤è¤êMPS III-A·¿¡ÁIII-D·¿¤Î4¤Ä¤Î°¡·¿¤ËʬÎव¤ì¤ë¤¬¡¢Î×¾²¾É¾õ¤Ï¤Û¤È¤ó¤ÉƱ¤¸¡£½ÅÅÙ¤ÎÀº¿Àȯã¤ÎÃÙÂÚ¤¬¼ç¾É¾õ¤Ç¤¢¤ê¡¢¹ü¡¦´ØÀá°Û¾ï¤ä´Î磼ð¤È¤¤¤Ã¤¿¾É¾õ¤Ï·ÚÅÙ¡£¥µ¥ó¥Õ¥£¥ê¥Ã¥Ý¾É¸õ·²Sanfilippo syndrome
AR ¥À¥Ã¥¯¥¹¡¢NZ¥Ï¥ó¥¿¥¦¥§¥¤
421 Mucopolysaccharidosis ­·B
¥à¥³Â¿Åü¾É­·B·¿
Ʊ¾å Genes: NAGLU
·ç»¹ÚÁǤÏIII-B·¿¡§¦Á-N-¥¢¥»¥Á¥ë¥°¥ë¥³¥µ¥ß¥Ë¥À¡¼¥¼
AR ¥¹¥­¥Ã¥Ñ¡¼¥­
422 Mucopolysaccharidosis ­º
¥à¥³Â¿Åü¾É­º·¿
¿åƬ¾É¡¢¶»¹ü´ñ·Á Genes: ARSB
N-acetylgalactosamine-4-sulfatase(N-¥¢¥»¥Á¥ë¥¬¥é¥¯¥È¥µ¥ß¥ó-4-¥¹¥ë¥Õ¥¡¥¿¡¼¥¼)·ç»¤Ë¤è¤ë¥Ç¥ë¥Þ¥¿¥óβ»À¤ÎÃßÀÑ¡£¥Ï¡¼¥é¡¼¾É¸õ·²¤ÈƱÍͤξɾõ¡£ ¥Þ¥í¥È¡¼¡¦¥é¥ß¡¼¾É¸õ·²Maroteaux-Lamy syndrome
AR ¥ß¥Ë¥Ô¥ó¡¢Ç­
423 Mucopolysaccharidosis ­»
¥à¥³Â¿Åü¾É­»·¿
4½µÎð¤Çû¤¯ÂÀ¤¤´é¡¦¡¦²£Êý¸þ¤Ë¹­¤¤¶»¡¦Ä㤤¼ªÉÕ¤­¡¢8½µÎð¤Ç¤Ó¤Þ¤óÀ­³ÑË캮Âù¡¢9½µÎð¤Ç¤Ï²áÅÙ¤ËÂ礭¤ÊƬÉô¡¦¤½¤Î¸¤¼ï¤ÎÄ̾ï¤Î»Ò¸¤¤ÎȾʬÄøÅÙ¤ÎÂ礭¤µ Genes:GUSB
¦Â-glucuronidase·ç»¤Ë¤è¤ë¥à¥³Â¿ÅüÎà¤ÎÁÈ¿¥ÆâÃßÀÑ¡£¥¹¥é¥¤É¡¢¥¹¥é¥¤¾É¸õ·²Sly syndrome
AR G¥·¥§¥Ñ
482 Neuronal ceroid lipofuscinosis, 1
¿À·Ð¥»¥í¥¤¥É¥ê¥Ý¥Õ¥¹¥Á¥ó¾É1·¿
Ä̾ÎCL¾É
À¸¸å7¥ö·îº¢¤«¤é9¥ö·îº¢¤Þ¤Ç¤Ë¹ÔÆ°¤ÎÊѲ½¡¢¿À·Ð²áÉÒ¡¢¸«Åö¼±¾ã³²¡¢±¿Æ°¼ºÄ´¡¢Ã¦ÎÏ´¶¡¢¸å׿¾É¡¢Êâ¹Ô¤Î¹äÀ­¡¢À©¸æÉÔǽ¤Ê¥ê¥º¥ß¥«¥ë¤ÊƬ¤ÎÆ°¤­¡¢»ë³Ð¾ã³²(ÌÖËì·ì´É¤ÎÊÑÀ­) Genes:PPT1
¥é¥¤¥½¥¾¡¼¥à¼À´µ¡£NCL1¤¬Ãø¤·¤¯·ç»¤·¥Ñ¥ë¥ß¥È¥¤¥ë¥×¥í¥Æ¥¤¥ó¥Á¥ª¥¨¥¹¥Æ¥é¡¼¥¼¡ÊPPT1¡Ë¤Î³èÆ°¤Ë¤è¤Ã¤Æ°ú¤­µ¯¤³¤µ¤ì¤ë¥À¥Ã¥¯¥¹¥Õ¥ó¥È¤Î°äÅÁÀ­¼À´µ
AR ¥À¥Ã¥¯¥¹¤Î¤ß
483 Neuronal ceroid lipofuscinosis, 10
¿À·Ð¥»¥í¥¤¥É¥ê¥Ý¥Õ¥¹¥Á¥ó¾É10·¿
Ä̾ÎCL¾É
2ºÐÁ°¤«¤é¬Äê²áÂç¾É¡¢Â¬Äê¾ã³²¡¢Ëãáã¡¢±¿Æ°¼ºÄ´¡¢¤ª¤è¤Ó¿Ê¹ÔÀ­Àº¿À±¿Æ°¤ÎÊÑÀ­ Genes:CTSD
¥é¥¤¥½¥¾¡¼¥à¼À´µ¡£Â¾¤ÎCLɤ˸«¤é¤ì¤Æ¤¤¤ëǾµ¡Ç½¾ã³²¤ä¼ºÌÀ¤Ïµ¯¤³¤é¤Ê¤¤¤¬7ºÐ¤Þ¤Ç¤Ë¤Ï»àË´
AR ¥¢¥á¥ê¥«¥ó¥Ö¥ë¥É¥Ã¥°¤Î¤ß
484 Neuronal ceroid lipofuscinosis, 12
¿À·Ð¥»¥í¥¤¥É¥ê¥Ý¥Õ¥¹¥Á¥ó¾É12·¿
Ä̾ÎCL¾É
ÃæÄøÅ٤λëÎϾ㳲¡¢¹ÔÆ°¤ÎÊѲ½¡¢Ç§Ãε¡Ç½¤ÎÄã²¼¡¢¾®Ç¾¼ºÄ´¡¢ÃÔÊò¡¢¤Æ¤ó¤«¤óÍÍȯºî¡¢¿À·Ð²áÉÒ¡¢¹¶·âÀ­¡¢µ­²±ÁÓ¼º¡¢»É·ã¤ËÂФ¹¤ë²áÉÒÀ­¡¢¿Ì¤¨ Genes: ATP13A2
¥é¥¤¥½¥¾¡¼¥à¼À´µ¡£4ºÐ¡Á6ºÐ¤Ëȯ¾É¡¢È¯¾É¸å¤ÏÁá´ü»àË´
AR ¥Á¥Ù¥¿¥ó¥Æ¥ê¥¢
485 Neuronal ceroid lipofuscinosis, 2
¿À·Ð¥»¥í¥¤¥É¥ê¥Ý¥Õ¥¹¥Á¥ó¾É2·¿
Ä̾ÎCL¾É
¿Ê¹ÔÀ­¤Î»ëÎÏÄã²¼¡¢¶¼°Ò¤Î±þÅú¡¢Æ¬Éô¤Î¿¶Àï¡¢¥ß¥ª¥¯¥í¡¼¥Ì¥¹¡¢¾®Ç¾À­±¿Æ°¼ºÄ´¡¢Â¿Æ°¡¢¹¶·âÀ­Áý²Ã¡¢°ÕÌ£¤¬¤ï¤«¤é¤Ê¤¤Ëʤ¨ Genes:cln5,CLN8TPP1
¥é¥¤¥½¥¾¡¼¥à¼À´µ¡£À¸¸å6¡Á7¥ö·î¤Ë¿Ê¹ÔÀ­¤Î»ëÎϾ㳲¤¬»Ï¤Þ¤ë¡¢8¥ö·îº¢¤Ë¥ß¥ª¥¯¥í¡¼¥Ì¥¹¤Æ¤ó¤«¤ó¡¦Æ¬Éô¿¶Àï¡¢9¥ö·îº¢¤«¤é¾®Ç¾À­±¿Æ°¼ºÄ´¡¢µÞ®¤Ë¿Ê¹Ô¤·¤Æ1ºÐ¤Þ¤Ç¤Ë»àË´
¥Ò¥ÈCLN2¤Î¥ª¥ë¥½¥í¥°(¶¦ÄÌÁÄÀè¤ò»ý¤Ä°Û¼ï´Ö¤ÎÁêƱ°äÅÁ»Ò)¡¡
AR ML¥À¥Ã¥¯¥¹
486 Neuronal ceroid lipofuscinosis, 4A
¿À·Ð¥»¥í¥¤¥É¥ê¥Ý¥Õ¥¹¥Á¥ó¾É4A·¿
Ä̾ÎCL¾É
¿Ê¹ÔÀ­»ëÎϾ㳲¡¢¹ÔÆ°¤ÎÊѲ½¡¢Àº¿À¤Î°­²½¡¢Ç§Ãα¿Æ°¤ÎÊÑÀ­¡¢±¿Æ°¼ºÄ´¡¢¤Æ¤ó¤«¤óÍÍȯºî Genes:
¥é¥¤¥½¥¾¡¼¥à¼À´µ¡£5ºÐ¤Ê¤ÉÃÙ¤¯¤Ë¾É¾õ¤¬½Ð¤ë¤¬È¯¾É¸å¤Ï»àË´¡£2010ǯ¤ÎÄ´ºº¤Ç¤Ï¥¢¥á¥ê¥«¤È¥Õ¥é¥ó¥¹¤Î¥¢¥à¥¹¥¿¤Î50%¤¬¥­¥ã¥ê¥¢¡¼¤Ç¤¢¤Ã¤¿¡£9ÈÖÀ÷¿§ÂÎñ°ì¤ÎÎΰ衩Kufs' disease»²¾È
AR ¥¢¥á¥ê¥«¥ó¥¹¥¿¥Ã¥Õ¥©¡¼¥É¥·¥ã¡¼¥Æ¥ê¥¢¤Î¥Õ¥é¥ó¥¹·ìÅý
487 Neuronal ceroid lipofuscinosis, 5
¿À·Ð¥»¥í¥¤¥É¥ê¥Ý¥Õ¥¹¥Á¥ó¾É5·¿
Ä̾ÎCL¾É
¿Ê¹ÔÀ­»ëÎϾ㳲¡¢Â¿Æ°¡¢Ç§Ãξɡ¢¹¶·âÀ­¡¢¶¨Ä´¤ÎÁÓ¼º¡¢±¿Æ°¼ºÄ´ Genes:cln5
¥é¥¤¥½¥¾¡¼¥à¼À´µ¡£2ºÐÁ°¸å¤Çȯ¾É¤·¡¢3ºÐ¤Þ¤Ç¤Ë»àË´
AR ¥Ü¡¼¥À¡¼¥³¥ê¡¼
488 Neuronal ceroid lipofuscinosis, 6
¿À·Ð¥»¥í¥¤¥É¥ê¥Ý¥Õ¥¹¥Á¥ó¾É6·¿
Ä̾ÎCL¾É
¿Ê¹ÔÀ­»ëÎϾ㳲¤Î¸å¼ºÌÀ¡¢Ç§Ãα¿Æ°¤ÎÊÑÀ­¡¢Àû²ó¡¢¶¨Ä´±¿Æ°¼ºÄ´ Gene: CLN6
¥é¥¤¥½¥¾¡¼¥à¼À´µ¡£È¯¾ÉǯÎð¤Ï2ºÐÁ°¤¯¤é¤¤
AR A¥·¥§¥Ñ
489 Neuronal ceroid lipofuscinosis, 7
¿À·Ð¥»¥í¥¤¥É¥ê¥Ý¥Õ¥¹¥Á¥ó¾É7·¿
Ä̾ÎCL¾É
* Genes:CLN8
¥é¥¤¥½¥¾¡¼¥à¼À´µ
AR ¥Á¥ã¥¤¥¯¥ì
490 Neuronal ceroid lipofuscinosis, 8
¿À·Ð¥»¥í¥¤¥É¥ê¥Ý¥Õ¥¹¥Á¥ó¾É8·¿
Ä̾ÎCL¾É
¿Ê¹ÔÀ­»ëÎϾ㳲¡¢¤Æ¤ó¤«¤óÍÍȯºî¡¢¿À·Ð¾ã³² Genes:CLN8
¥é¥¤¥½¥¾¡¼¥à¼À´µ¡£È¯¾É¸åÁá´ü»àË´
AR E¥»¥Ã¥¿¡¼
491 Neuronal Ceroid Lipofuscinosis, generic
¿À·Ð¥»¥í¥¤¥É¥ê¥Ý¥Õ¥¹¥Á¥ó¾É
Ä̾ÎCL¾É
°Û¾ï¹ÔÆ°¡¢Ç§Ãξɡ¢»ëÎϤÎÄã²¼¡¢±¿Æ°¾ã³²¤äáÛڻȯºî¡¢Áá´ü»àË´ Genes:cln5,CLN8
¥é¥¤¥½¥¾¡¼¥à¼À´µ¡£CLɤΤޤȤá¤Î¤è¤¦¤Ê¹àÌÜ
AR ¥»¥Ã¥¿¡¼¡¢¥Ü¡¼¥À¡¼¥³¥ê¡¼¡¢¥´¡¼¥ë¥Ç¥ó¥ì¥È¥ê¥Ð¡¼¡¢¥ª¡¼¥¹¥È¥é¥ê¥¢¥ó¥­¥ã¥È¥ë¥É¥Ã¥°¡¢¥µ¥ë¡¼¥­¡¢¥Á¥ï¥ï¡¢¥Á¥Ù¥¿¥ó¥Æ¥ê¥¢¡¢¥À¥Ã¥¯¥¹¥Õ¥ó¥É¡¢¥ß¥Ë¥Á¥å¥¢¥·¥å¥Ê¥¦¥¶¡¼
500 Niemann-Pick disease
¥Ë¡¼¥Þ¥ó¥Ô¥Ã¥¯ÉÂ
¿·À¸»ù´ü;ÂÛ»ùÊ¢¿å¡¢´Î磼𡢴ÎÉÔÁ´¤ä¸ÆµÛº¤Æñ¤Ç»àË´¡£
Íĸ¤´ü;¥Ê¥Ã¥¯¥ê¥ó¥°¡¢¥Ð¥é¥ó¥¹ÁÓ¼º¡¢Ãæ¿õ¿À·Ð¾É¾õ¡¢´Î磼ð¡¢áÛÚ»
¥é¥¤¥½¥¾¡¼¥à¼À´µ¡¢»é¼ÁÂå¼Õ°Û¾ï¾É¡£»ÀÀ­¥¹¥Õ¥£¥ó¥´¥ß¥¨¥ê¥Ê¡¼¥¼·ç»¤Ë¤è¤ë°äÅÁÀ­¤ÎºÙ˦Æâ»é¼ÁÃßÀÑ¾É AR *
501 Niemann-Pick disease, type A
¥Ë¡¼¥Þ¥ó¥Ô¥Ã¥¯ÉÂA·¿
´Î磼ð¡¢À®Ä¹ÉÔÁ´¡¢µÞ®¤Ê¿Ê¹ÔÀ­¤Î¿À·ÐÊÑÀ­¤ÇÁá´ü»àË´ »ÀÀ­¥¹¥Õ¥£¥ó¥´¥ß¥¨¥ê¥Ê¡¼¥¼¤¬Â礭¤¯·ç»¡£¥Ò¥È¤Ç¤Î³ÎÄê¿ÇÃǤϴÎ磼ð¤òǧ¤á¤¿¾å¤ÇÇò·ìµå¤Ç¤Î¥¹¥Õ¥£¥ó¥´¥ß¥¨¥ê¥Ê¡¼¥¼¤ÎÄêÎ̤«¤é²Äǽ AR ¥×¡¼¥É¥ë¡¢Ç­¡¢µí¡¢¥¢¥é¥¤¥°¥Þ
502 Niemann-Pick disease, type C
¥Ë¡¼¥Þ¥ó¥Ô¥Ã¥¯ÉÂC·¿
ȯ¾ÉǯÎð¤Ï¤Þ¤Á¤Þ¤Á¡£Ã×̿Ū¼À´µ ºÙ˦¤ÎÃæ¤Ç¥³¥ì¥¹¥Æ¥í¡¼¥ë¤ä¾¤Î»é¼Á¤òŬÀÚ¤ËÂå¼Õ¤µ¤»¤ë¤³¤È¤¬¤Ç¤­¤Ê¤¤¤¿¤á ´Î¡¤äç£Â¡¤ÎÃæ¤Ë¥³¥ì¥¹¥Æ¥í¡¼¥ë¤¬²áÅÙ¤ËÃßÀѤµ¤ì¡¢Ç¾¤Ë¤ª¤¤¤Æ¾¤Î»é¼Á¤ÎÎ̤¬²áÅÙ¤ËÁý¤¨¤ë¡£ AR *
513 Onychomadesis, symmetrical
ÂоÎÀ­ÄÞ¹ÃæÍî¾É
ÄÞ¤¬Çí¤¬¤ì¤ë¡¢³ä¤ì¤ë¡¢¤È¤ì¤ë ¹Ã¾õÁ£µ¡Ç½Äã²¼¾É¤ÈÇò·ìµå¹³¸¶¡ÊDLA¡Ë¥¯¥é¥¹­¶¤ÈÄÞ¹ÃæÍî¤ÎÀøºßŪ´ØÏ¢À­¤Î¸¦µæ¡£¡Ê¹Ã¾õÁ£µ¡Ç½Äã²¼¾É¤ÏDLA°äÅÁ»Ò¤¬Â¾¤Î°ø»Ò¤È¤È¤â¤ËÉ°ø¤Ë´ØÍ¿¤·¤Æ¤¤¤ë²ÄǽÀ­¤¬¤¢¤ëÊ£»¨¤Ê¼À´µ¡Ë¡£Çò·ìµå¹³¸¶¤Ï¥Ò¥È¤Î¾ì¹çHuman Leukocyte Antigen¡¢Ä̾ïHLA·¿¤È¸Æ¤Ð¤ì¹ü¿ñ°Ü¿¢¤ÎºÝ¤ËÈó·ì±ï¼Ô´Ö¤ÎŬ¹ç³ÎΨ¤¬¿ôÀé¡Á¿ôËüʬ¤Î°ì¤È¤¤¤ï¤ì¤Æ¤¤¤ë¥¢¥ì¤Ç¡¢¸¤¤â¤½¤Î·¿¤Î¼ïÎà¤Ï¿¤¤ unknown E¥»¥Ã¥¿¡¼¡¢G¥»¥Ã¥¿¡¼
535 Pancreatic insufficiency, exocrine
ç¹³°Ê¬ÈçÉÔÁ´
ÓÒÅÇ¡¦²¼Î¡¡¦Á餻¡¦Ê¢ÄË¡¦¹¶·âÀ­ ÊÌ̾ç¹Â¡°à½Ì¡¦ç¹Â¡Á£Ë¼°à½Ì¡£1¡Á3ºÐ¤Î´Ö¤Ë¸«¤é¤ì¤ä¤¹¤¯¡¢ºÇ½é¤Ï¿©Íߤ¬ÊѤï¤é¤Ê¤¤¤Î¤ËÂνŤ¬¸º¾¯¤¹¤ë¡¢²¼Î¡¤Ï³¥¿§¤Ã¤Ý¤¯Ìý¤Ã¤Ý¤¤½­¤¤¤Î»éËÃÊØ¡¢ç¹¾Ã²½¹ÚÁÇʬÈç¤Î¸º¾¯¡£ç¹Â¡¤ÎÁ£Ë¼¤Î³°Ê¬È絡ǽ¤ÎÁÓ¼º¤Ë¤è¤ê¾Ã²½¹ÚÁǤ¬Ê¬È礵¤ì¤Ê¤¯¤Ê¤ë¤³¤È¤ò¸¶°ø¤È¤¹¤ë¾Ã²½µÛ¼ýÉÔÎÉ¡£¾Ã²½ÉÔÎɤˤè¤ë±ÉÍÜÉÔÎɤÇÈéÉæ¤Î´¥Á硦ÉÏÌÓ¡¦Ã¦ÌÓ¡¦ÀÖ·ìµå¸½¾Ý¡¦¶ÚÆù¤Î¸º¾¯¤Ê¤É¤Ë¿Ê¤à AR G¥·¥§¥Ñ
549 Persistence of immature pyruvate kinase and hexokinase isozymes
*̤½Ï·¿¥Ô¥ë¥Ó¥ó»À¥­¥Ê¡¼¥¼µÚ¤Ó¥Ø¥­¥½¥­¥Ê¡¼¥¼¤Î¥¢¥¤¥½¥¶¥¤¥à»Äα
* * unknown *
600 Pyruvate dehydrogenase deficiency
¥Ô¥ë¥Ó¥ó»À¥­¥Ê¡¼¥¼·ç˳¾É
»à»º¡¦¿·À¸»Ò»àË´¡£Æý»À¤ÎÃßÀѤˤè¤ë¶ÚÎÏÄã²¼¡¢´Î¾ã³²¡¢¤±¤¤¤ì¤óȯºî¡¢ATP(¥¢¥Ç¥Î¥·¥ó»°¥ê¥ó»À)»ºÀ¸Äã²¼¡¢ÀÖ·ìµåÆâæ¿å¡¢ç£¼ð PK·ç»¾É¡£±¿Æ°¤ä´¶À÷¾É¤Ç°­²½¡¢¥Ò¥È¤Î¾ì¹ç¤Ï´Î¡¤Þ¤¿¤ÏÈéÉæ¤ÎºÙ˦¤Î¹ÚÁdzèÀ­¤ò¬Äꤹ¤ë¤³¤È¤Ç¿ÇÃÇ(Ëö¾¿·ìɸËܤÇÍ­ÛùÀÖ·ìµå¤¬¸«¤é¤ì¤ë)¡¢¼£ÎŤÏç£Â¡Å¦½Ð AR ¥¯¥é¥ó¥Ð¡¼¡¢¥µ¥»¥Ã¥¯¥¹¥¹¥Ñ¥Ë¥¨¥ë
601 Pyruvate kinase deficiency of erythrocyte
ÀÖ·ìµå¥Ô¥ë¥Ó¥ó»À¥­¥Ê¡¼¥¼·ç˳¾É
ÃæÅùÅ٤δÎ磼𡢿ʹÔÀ­¹ü¹Å²½¾É¡¢¹ü¿ñÀþ°Ý¾É²«áÕ¡¢°äÅÁÀ­ÍÏ·ìÀ­ÉÏ·ì¤Î¹çÊ» Genes:PKLR
»à»º¡¦¿·À¸»Ò»àË´¤â¤¢¤ë¤¬5ºÐ°Ê¾å¤Çȯ¾É¤¹¤ë¥±¡¼¥¹¤â¿¤¤¡£ATP»ºÀ¸Äã²¼¤ÇÀÖ·ìµå¤Îæ¿å¤¬µ¯¤­ç£¼ð
AR ¥Ð¥»¥ó¥¸¡¼¡¢¥Ó¡¼¥°¥ë¡¢¥±¥¢¥ó¡¢¥¦¥¨¥¹¥Æ¥£
604 Reduced glutathione deficiency, unclassified
*̤ʬÎà¤Î´Ô¸µ·¿¥°¥ë¥¿¥Á¥ª¥ó·ç»
¶Ì¤Í¤®¤ËͶȯ¤µ¤ì¤ëÍÏ·ì ¶Ì¤Í¤®ÃæÆǤδ¶¼õÀ­¡¢·ì±Õ¤Î¹ÚÁǰ۾Ë̳¤Æ»Âç³Ø¤Ç¸¦µæ¤¢¤ê¡£´ðËÜŪ¤Ë̵¾É¾õ¤ÇÌôÉʤäºÙ¶Ý´¶À÷¤ä¤¢¤ë¿©ÉʤÎÀ®Ê¬(¥Ò¥È¤Ç¤Ï¥½¥é¥Þ¥á)¤¬ÍÏ·ì¤òͶ°ú¤¹¤ë¡£´Ô¸µ·¿¥°¥ë¥¿¥Á¥ª¥ó(GSH)¤ÏNADPH(¥Ë¥³¥Á¥ó¥¢¥ß¥É¥¢¥Ç¥Ë¥ó¥¸¥Ì¥¯¥ì¥ª¥Á¥É¥ê¥ó»À)¤È¤È¤â¤ËÀÖ·ìµå¤Î»À²½¤òËɤ°Ìò³ä¤ò¤¹¤ë¹ÚÁÇ
·ì±Õ¤Î¹ÚÁǰ۾´ðËÜŪ¤Ë̵¾É¾õ¤ÇÌôÉʤäºÙ¶Ý´¶À÷¤ä¤¢¤ë¿©ÉʤÎÀ®Ê¬(¥Ò¥È¤Ç¤Ï¥½¥é¥Þ¥á)¤¬ÍÏ·ì¤òͶ°ú¤¹¤ë¡£´Ô¸µ·¿¥°¥ë¥¿¥Á¥ª¥ó(GSH)¤ÏNADPH(¥Ë¥³¥Á¥ó¥¢¥ß¥É¥¢¥Ç¥Ë¥ó¥¸¥Ì¥¯¥ì¥ª¥Á¥É¥ê¥ó»À)¤È¤È¤â¤ËÀÖ·ìµå¤Î»À²½¤òËɤ°Ìò³ä¤ò¤¹¤ë¹ÚÁÇ
unknown *
639 Sodium-potassium-ATPase, high activity
*¥Ê¥È¥ê¥¦¥à-¥«¥ê¥¦¥à* ¥¢¥Ç¥Î¥·¥ó»°¥ê¥ó»Àʬ²ò¹ÚÁÇ(ATP¥¢¡¼¥¼)*¹â³èÀ­(³èÆ°)
* * unknown *
678 Thyroiditis
¹Ã¾õÁ£±ê
¹Ã¾õÁ£¤Î¼ðı¡¢ÄË¤ß ¼«¸ÊÌȱּÀ´µ¤Ê¤É¤Ç¹Ã¾õÁ£¤¬±ê¾É¤òµ¯¤³¤¹(¶¶ËÜÉÂ) unknown *
705 Wilson disease
¥¦¥£¥ë¥½¥óÉÂ
* Genes:ATOX1,COMMD1
Ƽ¤ÎÃßÀѤòÍ褹°äÅÁÀ­¼À´µ
AR *
706 Wilson disease, COMMD1 type
COMMD1·¿¡¡¥¦¥£¥ë¥½¥óÉÂ
* * unknown *


¤³¤Î¥Ú¡¼¥¸¤ÎÀèƬ¤ËÌá¤ë****** Á°¤Î¥Ú¡¼¥¸****** ¼¡¤Î¥Ú¡¼¥¸